CSL Limited’s
(ASX:CSL) first half net profit has increased 24 per cent to $609 million and the vaccine maker has reaffirmed its full year profit growth outlook of 20 per cent.
Earnings were boosted by increased demand for blood derived treatments, with CSL’s sales rising 11 per cent to $US2.48 billion.
CEO Dr Brian McNamee says CSL had strengthened its presence in emerging markets over the first half, while ongoing efficiency initiatives had underpinned long term margin improvement.
Dr Mcnamee said while global business conditions remain mixed, the blood products and vaccine maker will maintain its full year profit guidance, and expects earnings per share growth to exceed profit growth, with shareholders benefiting from past and current capital management initiatives.
CSL will pay its shareholders an unfranked interim dividend of 50 cents.
